As CKD progresses, the compensation of elevations in PTH and fibroblast growth factor-23 (FGF-23) and decreased levels of 1,25(OH)2D3 becomes inadequate and inappropriate, resulting in hyperphosphatemia, abnormal bone, and extraskeletal calcification. Here, FGF23 is linked to hyperphosphatemia.